Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DA79HM
|
|||
| Drug Name |
SB 11285
|
|||
| Indication | Head-neck squamous cell carcinoma [ICD-11: 2D60.0; ICD-10: C77.0] | Phase 1 | [1] | |
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1 | [1] | ||
| Company |
F-star Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Stimulator of interferon genes protein (TMEM173) | Target Info | Agonist | [2] |
| KEGG Pathway | NOD-like receptor signaling pathway | |||
| RIG-I-like receptor signaling pathway | ||||
| Cytosolic DNA-sensing pathway | ||||
| Human cytomegalovirus infection | ||||
| Herpes simplex virus 1 infection | ||||
| Human immunodeficiency virus 1 infection | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04096638) Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of F-star Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.